Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Fig. 3

Kaplan Meier curve comparing OS for 55 patients from the next line of systemic therapy for kidney cancer after discontinuation of IO-VEGF by prior received IO-TKI vs. IO-Bev with no statistical difference between the groups (Log-rank p = 0.73). OS (Overall Survival), IO-VEGF (Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy), IO-TKI (IO-Tyrosine Kinase Inhibitor), IO-Bev (IO-Bevacizumab)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us